Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme

Oncotarget
Sabrina HeynckesDieter Henrik Heiland

Abstract

The biology of recurrent glioblastoma multiforme (GBM) is a dynamic process influenced by selection pressure induced by different antitumoural therapies. The poor clinical outcome of tumours in the recurrent stage necessitates the development of effective therapeutic strategies. Checkpoint-inhibition (PD1/PD-L1 Inhibition) is a hallmark of immunotherapy being investigated in ongoing clinical trials. The purpose of this study was to analyse the PD-L1 expression in de-novo and recurrent glioblastoma multiforme and to explore associated genetic alterations and clinical traits. We show that PD-L1 expression was reduced in recurrent GBM in comparison to de-novo GBM. Additionally, patients who received an extended dose of temozolomide (TMZ) chemotherapy showed a significantly reduced level of PD-L1 expression in the recurrence stage compared to the corresponding de-novo tumour. Our findings may provide an explanation for potentially lower response to immunotherapy in the recurrent stage due to the reduced expression of the therapeutic target PD-L1.

References

Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 27, 2012·PloS One·Gabrielle C NickelThomas LaFramboise
Nov 8, 2012·Clinical & Developmental Immunology·Sadhak SenguptaPrakash Sampath
Jan 10, 2014·Cancer Medicine·David F McDermott, Michael B Atkins
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Mar 8, 2014·Oncoimmunology·Stéphane ChampiatJean Charles Soria
Oct 31, 2014·Neuro-oncology·Anna Sophie BerghoffWolfgang Wick
Nov 14, 2014·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Zoran GatalicaOmid Hamid
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Dec 3, 2014·Trends in Molecular Medicine·Kim C OhaegbulamXingxing Zang
Sep 2, 2015·Neuro-oncology·Edjah K NduomAmy B Heimberger
Mar 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric BouffetUri Tabori
Dec 30, 2016·Neuro-oncology·Robert L BowmanMassimo Squatrito
Feb 9, 2017·Oncotarget·Dieter Henrik HeilandOliver Schnell

❮ Previous
Next ❯

Citations

Sep 27, 2018·Neurologia Medico-chirurgica·Shabierjiang JiapaerMitsutoshi Nakada
Jun 4, 2020·Cellular Oncology (Dordrecht)·Łukasz ZadkaPiotr Dzięgiel
Jan 29, 2019·Frontiers in Pharmacology·Ruo Qiao ChenXiao Qian Chen
Sep 18, 2021·Neuropathology and Applied Neurobiology·Gayaththri Vimalathas, Bjarne Winther Kristensen

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
biopsy
PCR

Software Mentioned

R
ImageJ
software

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
Chao ChenShenhong Wu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D OsobaM Prados
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Nu ZhangSuyun Huang
© 2022 Meta ULC. All rights reserved